Skye Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SKYE research report →
Range $2 – $21
Price Chart
About the company
Skye Bioscience, Inc. , a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
- CEO
- Punit Dhillon
- IPO
- 2015
- Employees
- 2
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on SKYE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.10M
- P/E
- -0.10
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 2.87
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -503.95%
- ROIC
- -3183.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-723,352+0.0%
- Op Income
- $-58,163,565
- Net Income
- $-55,924,814-110.5%
- EPS
- $-11.28-93.2%
- OCF Growth
- -70.6%
- FCF Growth
- -60.5%
- 52W High
- $11.04
- 52W Low
- $0.49
- 50D MA
- $1.47
- 200D MA
- $4.38
- Beta
- 3.15
- RSI (14)
- 32
- Avg Volume
- 85.65K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Skye Bioscience said its nimacimab program is moving from a 200 mg exposure question to higher-dose and formulation work, with combination data continuing to support an add-on obesity strategy.· March 10, 2026
- CBeyond combination data showed nimacimab plus semaglutide delivered 3% more weight loss than semaglutide alone at 26 weeks, with 22.3% mean weight loss in the 52-week extension and no plateau observed.
- Management said the 200 mg weekly monotherapy dose underexposed peripheral tissues, framing the modest 1.5 reduction at 26 weeks as an exposure issue rather than a pathway issue.
- Skye is starting a CBeyond Part C expansion with 400 mg and 600 mg IV cohorts to generate higher-exposure PK and safety data and monitor neuropsychiatric events.
- The company is also advancing Halozyme ENHANZE work for a practical subcutaneous path in Phase IIb and said it expects that work to be ready for Phase IIb.
- Early APC data showed additive weight loss and proof of concept for a unimolecular dual-mechanism platform, with 3-day dosing achieving efficacy comparable to a daily combination regimen.
No quarterly revenue, EPS, gross margin, or year-over-year operating figures were provided in the transcript. Management said Skye ended 2025 with $25.7 million in cash, cash equivalents and short-term investments, and said it is managing the operating plan to extend runway through Q4 2026. Forward-looking clinical milestones include interim CBeyond extension data in Q1, completion of ENHANZE compatibility and in-use work, Cohort 2 enrollment in Q2, and top-line expansion study data plus planned Phase IIb final study design in Q4 2026.
Punit Dhillon emphasized that Skye has moved from an initial signal to a more coherent development case for nimacimab, especially as an add-on to GLP-1 therapy rather than a competing first-line obesity drug. His tone was confident but measured: he repeatedly framed the next step as proving the exposure-safety-durability relationship at higher doses and building a practical subcutaneous path before Phase IIb. He also highlighted capital discipline, saying the company had aligned costs to the work that matters most and is targeting runway through Q4 2026.
No formal CFO remarks were included, but management comments covered cash and capital allocation. Punit Dhillon said Skye ended 2025 with $25.7 million in cash, cash equivalents and short-term investments, and that the company has been managing its operating plan to extend runway through Q4 2026. He also said the team took steps to align the cost structure with the highest-priority R&D and clinical work, including the new CBeyond expansion and Phase IIb planning.
Analysts focused on how quickly Skye can share higher-dose data, whether the company needs even higher doses, and how the Halozyme-enabled formulation will work. Management said the Part C IV cohorts are the fastest way to generate high-exposure safety and PK data, with doses selected to confirm a clear exposure step-up and preserve CNS sparing; they said efficacy is not the primary readout, though any monotherapy directionality would matter. On formulation, management said ENHANZE work is ongoing and intended for Phase IIb, while IV is being used now to accelerate data generation; they also confirmed a self-administered or commercial-type delivery path would be addressed later, with an auto-injector concept tied to Phase III rather than the current study.
The call reinforced a differentiated niche for nimacimab as an orthogonal add-on for GLP-1-experienced patients who still need more weight loss, better durability, or improved body composition. Management also pointed to clean tolerability, no nimacimab-associated neuropsychiatric signal through 52 weeks, and early APC proof of concept that could broaden the platform beyond the core obesity program.
The key risk is that the current 200 mg monotherapy result did not deliver the efficacy management wants, and the company is still trying to prove that higher peripheral exposure translates into better weight loss. The program also remains early and dependent on upcoming PK/safety readouts, formulation work, and regulatory alignment before Phase IIb, while the company has only $25.7 million in cash and is relying on a runway-through-Q4-2026 plan.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 71.1%
- Shares Outstanding
- 4.42M
- Float Shares
- 3.14M
of shares held by institutions
45 13F filers
Buy/sell ratio 0.04. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| 5am Venture Management, LLC | 981.27K | ▼ 8.70M |
| Vanguard Group Inc | 882.78K | 0 |
| Sphera Funds Management Ltd. | 678.93K | 0 |
| Versant Venture Management, LLC | 250.96K | ▼ 1.76M |
| Tang Capital Management LLC | 200.00K | ▲ 200.00K |
| Baker Bros. Advisors LP | 196.91K | ▼ 1.38M |
| Citadel Advisors LLC | 114.94K | ▲ 114.94K |
| Northern Trust Corp | 56.33K | ▲ 36.19K |
| Two Sigma Advisers, LP | 40.98K | ▲ 40.98K |
| Ubs Group AG | 40.46K | ▼ 33.34K |
| Blackrock, Inc. | 29.11K | ▼ 203.77K |
| Geode Capital Management, LLC | 27.25K | ▼ 190.80K |
Held by 8 ETFs
Biggest fund positions in SKYE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 22, 26 | Schwab Andrew J. | sell | 27,612 |
| Sep 22, 26 | Schwab Andrew J. | sell | 1,088 |
| Sep 23, 26 | Schwab Andrew J. | sell | 4,528 |
| Sep 22, 26 | 5AM Partners VII, LLC | sell | 27,612 |
| Sep 22, 26 | 5AM Partners VII, LLC | sell | 1,088 |
| Sep 23, 26 | 5AM Partners VII, LLC | sell | 4,528 |
| Sep 16, 26 | Schwab Andrew J. | sell | 32,607 |
| Sep 16, 26 | Schwab Andrew J. | sell | 1,285 |
| Sep 16, 26 | 5AM Partners VII, LLC | sell | 32,607 |
| Sep 16, 26 | 5AM Partners VII, LLC | sell | 1,285 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SKYE coverage
Recent articles, reports, and earnings notes.
No research on SKYE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SKYE report →SKYE Stock Alert: Halper Sadeh LLC is Investigating Whether Skye Bioscience, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com · Nov 18
SPIN MASTER AND NICKELODEON ANNOUNCE NEW PAW PATROL® SPINOFF FEATURING SKYE
prnewswire.com · Nov 10
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
defenseworld.net · Sep 20
Andrew Schwab Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
defenseworld.net · Sep 20
Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx Therapeutics
defenseworld.net · Aug 19
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
seekingalpha.com · Aug 14
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
globenewswire.com · Aug 14
Skye Bioscience (NASDAQ:SKYE) Trading 2.8% Higher – Time to Buy?
defenseworld.net · Aug 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.